Severe Plaque Psoriasis Research Articles

Off-label uses of ustekinumab.

Ustekinumab (brand name Stelara®) is a human interleukin-12 and -23 antagonist and has been indicated for the treatments of moderate to severe plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis. This review aims to synthesize and interpret the literature evaluating the off-label uses of ustekinumab. We performed searches in PubMed and ClinicalTrials.gov for clinical trials, observational studies, case series, and case reports evaluating label uses of ustekinumab. Studies evaluated the efficacy of ustekinumab for the following conditions: other types of psoriasis (expect plaque psoriasis and psoriatic arthritis), pityriasis rubra pilaris, hidradenitis suppurativa, atopic dermatitis, pyoderma gangrenosum, et al. Based on the available literature, ustekinumab appears to be a potential treatment choice for many other diseases. However, more clinical trials data are needed to adequately assess the safety and efficacy of ustekinumab for the treatment of these conditions.

Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient.

A wide range of comorbid conditions are associated with psoriasis, many studies have drawn attention to a higher prevalence of psychiatric comorbidities in psoriatic population. Herein, we present a case of a Caucasian 44-years-old man suffering from a severe schizophrenia, who received guselkumab (a human monoclonal antibody targeting the p40 subunit of IL-23) for the treatment of a moderate-to-severe plaque type psoriasis. After 3 months, the patient reached complete resolution of psoriasis without any side effects, maintained at 6 months follow up visit. Some studies have highlighted the hypothesis that an hyperactivation of immune response appears to be one of the main mechanisms underlying the increased risk of this association. In particular, the axis il-17/il-23 plays a central role in the pathogenesis of this disease. Further research will be needed to assess whether anti-IL23 drugs could be a more suitable therapeutic option in psoriatic patients with schizophrenia.

164 Correlations between etiopathogenic factors and persistence of anti-IL-17A biologic therapies in patients with severe psoriasis vulgaris

In recent years, multiple biologic therapies with various mechanisms of action for the treatment of inflammatory diseases have been developed, including moderate to severe plaque psoriasis. The choice of the optimal treatment for psoriasis can depend on several factors and is strongly influenced by the effectiveness and safety profile of a drug. Thus, following an observational, non-interventional, retrospective study of patients with moderate to severe psoriasis receiving biological treatment with IL-17 inhibitors, we analyzed our experience in evaluating from real data the persistence of anti-IL-17A therapies and to identify the factors that may affect these patients.

134 The role of gut microbiota-derived metabolites in psoriasis

Gut microbiome alterations observed in patients with psoriasis might contribute to the disease pathogenesis through an increased intestinal permeability and translocation of several bacterial metabolites. The aim of the study was to assess the gut barrier dysfunction, concentration of intestinal microbiota-derived metabolites and their possible association with clinical manifestations and comorbidities of psoriasis. One hundred twenty patients with moderate to severe plaque psoriasis as well as 60 age- and weight-matched control were enrolled.

365 Secukinumab normalizes skin transcriptomes to a never-lesional state in new-onset psoriasis patients more rapidly than in chronic patients

Biological treatments targeting the IL-17A pathway have been assessed in patients with a long-term history of plaque psoriasis (PsO). We hypothesize that early systemic treatment with secukinumab may prolong treatment-free remission and alter the clinical outcome of PsO. The mechanistic sub-study of the STEPIn trial (NCT03020199) assessed molecular changes in the skin of patients with new-onset (≤12 months, naïve to systemic treatment) vs chronic (≥5 years since first symptoms) moderate to severe PsO who were randomized to receive secukinumab 300 mg or narrow-band ultraviolet B treatment.

Bimekizumab maintenance of response through three years in patients with moderate to severe plaque psoriasis who responded at Week 16: Results from the BE BRIGHT open-label extension trial

N/A

Indirect comparison of the short-, mid-, and long-term efficacy of treatments for moderate to severe plaque psoriasis: a systematic review and network meta-analysis

N/A

Bimekizumab efficacy and safety through three years in patients with moderate to severe plaque psoriasis: Long-term results from the BE SURE randomized controlled trial and the BE BRIGHT open-label extension

N/A

Treat-to-Target Outcomes and Measures of Treatment Success in Three Phase 3 Trials of Tapinarof Cream 1% Once Daily for Mild to Severe Plaque Psoriasis

N/A

Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)

N/A

Bimekizumab efficacy through one year in patients with moderate to severe plaque psoriasis in subgroups defined by prior biologic treatment: Pooled results from four phase 3/3b trials

N/A

Bimekizumab in patients with moderate to severe plaque psoriasis by bodyweight: Pooled results from phase 3 trials

N/A

Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: 52-week efficacy by prior treatment in the phase 3 POETYK PSO-1 trial

N/A

Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial

N/A

Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment in phase 3 and 3b clinical trials

N/A

Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials

N/A

Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: analysis of body surface area involvement in the phase 3 POETYK PSO-1 and PSO-2 trials

N/A

Optimizing the treatment sequence: the cumulative clinical benefit of treatment initiation with deucravacitinib versus apremilast over 52 weeks in patients with moderate to severe plaque psoriasis from the POETYK PSO-1 trial

N/A

Bimekizumab safety in patients with moderate to severe plaque psoriasis: Analysis of pooled data from up to three years of treatment in phase 2 and 3 clinical trials

N/A

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2

N/A